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Objective: This report presents a cross-sectional analysis of
the baseline characteristics of subjects with Leber hereditary optic neuropathy enrolled in the gene therapy trials
RESCUE and REVERSE, to illustrate the evolution of visual
parameters over the ﬁrst year after vision loss.
Methods: RESCUE and REVERSE were 2 phase III clinical trials
designed to assess the efﬁcacy of rAAV2/2-ND4 gene therapy in
ND4-LHON subjects. At enrollment, subjects had vision loss for
#6 months in RESCUE, and between 6 and 12 months in
REVERSE. Functional visual parameters (best-corrected visual
acuity [BCVA], contrast sensitivity [CS], and Humphrey Visual
Field [HVF]) and structural parameters assessed by spectraldomain optical coherence tomography were analyzed in both
cohorts before treatment. The cross-sectional analysis of functional and anatomic parameters included the baseline values
collected in all eyes at 2 different visits (Screening and Inclusion).
Results: Seventy-six subjects were included in total, 39 in
RESCUE and 37 in REVERSE. Mean BCVA was signiﬁcantly
worse in RESCUE subjects compared with REVERSE subjects
(1.29 and 1.61 LogMAR respectively, P = 0.0029). Similarly,
mean CS and HVF were signiﬁcantly more impaired in REVERSE
vs RESCUE subjects (P , 0.005). The cross-sectional analysis
showed that the monthly decrease in BCVA, ganglion cell layer
macular volume, and retinal nerve ﬁber layer thickness was
much more pronounced in the ﬁrst 6 months after onset (+0.24
LogMAR, 20.06 mm3, and 26.00 mm respectively) than
between 6 and 12 months after onset (+0.02 LogMAR,
20.01 mm3, and 20.43 mm respectively).
Conclusion: LHON progresses rapidly in the ﬁrst months
following onset during the subacute phase, followed by
relative stabilization during the dynamic phase.
Journal of Neuro-Ophthalmology 2021;41:298–308
doi: 10.1097/WNO.0000000000001316
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
on behalf of the North American Neuro-Opthalmology Society.
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eber hereditary optic neuropathy (LHON) is a maternally inherited blinding bilateral optic neuropathy
caused by mitochondrial DNA (mtDNA) missense point
mutations affecting complex I in the mitochondrial respiratory chain (1,2), resulting in selective dysfunction and subsequent apoptotic loss of retinal ganglion cells (RGCs) (3,4).
LHON is considered the most common disorder caused by a
mutation of the mitochondrial DNA (5). It typically affects
mostly young men causing painless, loss of central vision that
ultimately evolves into profound visual impairment (2–8). Eyes
are affected sequentially in 50%–75% of cases, with the second
eye involved within weeks or months after the ﬁrst. An initial
subacute phase, lasting approximately the ﬁrst 6 months after
onset, is characterized by a fairly rapid deterioration of visual
function (2). Once a nadir is reached, visual acuity stabilizes, but
other parameters, in particular optical coherence tomography
(OCT) measurements of retinal layer thickness, will still evolve,
deﬁning a dynamic phase over the next 6 months. About one
year after disease onset, the clinical picture enters a chronic phase
of relative stability (2). Usually, visual prognosis is poor and
most subjects reach acuities worse than 20/200 (2–4,6). The
most common (75%) and most severe clinical form of LHON
is caused by the m.11778G.A point mutation in the mtDNA
gene encoding nicotinamide adenine dinucleotide hydride dehydrogenase protein subunit 4 (ND4) (1–4,6). A recent metaanalysis of reports on the natural history of LHON in subjects
15 years and older carrying the m.11778G.A mutation established that spontaneous recovery of meaningful visual acuity
occurs in 11% of patients (9).
Recent advances in molecular biology allow for viral
transduction of affected RGCs, allotopic expression of the
Moster et al: J Neuro-Ophthalmol 2021; 41: 298-308
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ND4 wild-type protein from the nucleus and its cotranslocation into the mitochondrial matrix to complement
the mutant protein, offering the promise of restoration of
vision (10–13). rAAV2/2-ND4 is such a gene therapy administered as an intravitreal injection (IVT) for the treatment of
LHON caused by the m.11778G.A mutation. Treatment
with rAAV2/2-ND4 has been shown to be safe and well tolerated in early-phase and phase III clinical trials (14–16).
RESCUE
(NCT02652767)
and
REVERSE
(NCT02652780) were 2 Phase III clinical trials that investigated the efﬁcacy of rAAV2/2-ND4 in LHON subjects conﬁrmed to carry the m.11778G.A mutation, and with time
since onset of vision loss #6 months in RESCUE, and
between 6 months and 1 year in REVERSE. In this report,
we present the baseline characteristics of LHON subjects

enrolled in RESCUE and REVERSE, including bestcorrected visual acuity (BCVA), contrast sensitivity (CS), Humphrey Visual Field (HVF), and structural parameters assessed
by spectral-domain optical coherence tomography (SD-OCT).
Using cross-sectional analysis of functional and anatomic
parameters ascertained at the baseline of different timepoints,
we explore the correlations between duration of vision loss and
these parameters before any treatment administration.

METHODS
Study Design
RESCUE and REVERSE (ClinicalTrial.gov NCT02652767
and NCT026527080) (15,16) were 2 randomized, doublemasked, sham-controlled, multicenter, international, pivotal
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clinical trials to evaluate the efﬁcacy of a single IVT of
rAAV2/2-ND4 in subjects with LHON secondary to the
m.11778G.A mutation. Both protocols were prospectively reviewed and approved by independent ethics committees (the London—West London & Gene Therapy
Advisory Committee Research Ethics Committee in the
United Kingdom; the Comité de Protection des Personnes
in France; the Ethikkommission der Medizinischen Fakultät der Ludwig-Maximilians Universität München in Germany; the Comitato Etico Interaziendale Bologna-Imola in
Italy; the Wills Eye Hospital Institutional Review Board,
the Emory University Institutional Review Board, and
the University of California Los Angeles General Campus
Institutional Review Board in the United States), were
conducted in accordance with the principles and requirements of the International Conference on Harmonization
Good Clinical Practice and adhered to the Declaration of
Helsinki. Informed consent was obtained from patients
before inclusion in trials.

Study Population
The recruitment period for REVERSE and RESCUE was
from February 2016 to March and August 2017,
respectively.

Inclusion Criteria
To be included in either study, LHON subjects had to
harbor the m.11778G.A mutation, be at least 15 years
old at enrollment, and have vision of count ﬁngers or
better in both eyes. In RESCUE, one or both eyes could
be affected by vision loss provided the duration of vision
loss was #180 days in the affected eye(s) at screening. In
REVERSE, both eyes had to be affected by vision loss for
181–365 days at time of screening. The screening visit
occurred 28 to 1 day(s) before the inclusion visit, which
was performed the day before IVT administration. Documented genotyping was required to conﬁrm the presence
of the m.11778G.A mutation in the MT-ND4 gene and
the absence of other primary LHON-associated mutations (MT-ND1 or MT-ND6). Whole mitochondrial
genome sequencing was not performed. The subjects recruited into RESCUE and REVERSE had classical
LHON phenotypes and nuclear genome sequencing
was not speciﬁcally requested to exclude other optic atrophy genes.

Exclusion Criteria
The exclusion criteria included any previously known
inherited retinal or optic nerve conditions. Additional
exclusion criteria were previous treatment with an ocular
gene therapy product, glaucoma, optic neuropathy other
than LHON, history of amblyopia, previous vitrectomy
in either eye, or ocular surgery within 90 days. Prior use
of idebenone was required to have ceased at least 7 days
before inclusion. This was believed to be a sufﬁcient
300

length of time because idebenone is rapidly absorbed,
with an average plasma half-life of about 15 hours (17).

Assessments at Baseline
Demographic characteristics were collected before treatment, along with visual function and anatomic parameters.
Ophthalmic evaluations included BCVA using the EarlyTreatment Diabetic Retinopathy Study (ETDRS) charts at
1 or 4 m, assessment of CS using the Pelli–Robson chart,
HVF 30-2 testing, Farnsworth-Munsell 100-Hue Color
Vision testing, slit-lamp microscopy, Goldmann applanation tonometry, funduscopy, SD-OCT, and color fundus
photography. The predeﬁned baseline for functional visual
parameters (BCVA, CS, HVF, color vision) was the last
available assessment before treatment; for anatomic metrics
(OCT), the baseline was deﬁned as the average of values
measured at screening and inclusion visits. In this manuscript, to better characterize the evolution of these previous
parameters before treatment, we have included the values
both at screening (within one month before inclusion) and
at inclusion (one day before treatment).
When subjects could not read any letters on the ETDRS
chart, they were asked to count the assessor’s ﬁngers or to
detect hand motion. An off-chart Snellen equivalent was
derived using both the distance at which the assessment
was made and the size of the assessor’s ﬁngers, as described
by Karanjia et al (18) (this method was also adapted to hand
motion visual acuity), then was converted into a LogMAR
value. Light perception and no light perception visual acuities were assigned a value of 4.0 and 4.5 LogMAR,
respectively.
CS—the reciprocal of contrast threshold—was measured
using the Pelli–Robson chart at 1 m, performed according
to test instructions and expressed as a logarithm (LogCS)
(19). Subjects who could not read more than one letter of
the ﬁrst triplet on the Pelli–Robson chart were considered
off-chart, and the value assigned according to the statistical
analysis plan was the worst possible score (0 LogCS).
For visual ﬁeld assessment, the standardized automated
procedure HVF 30-2, Central Threshold, SITA-FAST was
performed using the HVF Analyzer II. A reading center
masked to treatment allocation (Optic Nerve Research
Center, William H Annesley Jr. EyeBrain Center, Thomas
Jefferson University) performed quality control, analysis,
and interpretation of all OCT and HVF data. The HVF test
was repeated if considered unreliable by the reading center
(i.e., ﬁxation losses $15%, false positive errors $20%, or
false negative errors $33%).
SD-OCT was performed with the Spectralis OCT
(Heidelberg Engineering). Among other parameters, retinal
nerve ﬁber layer (RNFL) and ganglion cell layer (GCL)
were measured for the optic nerve and posterior pole per
standard protocols included in the Spectralis software. At
prespeciﬁed visits, certiﬁed technicians performed one
“Optic Nerve Head—Radial Scan and Concentric Circle
Moster et al: J Neuro-Ophthalmol 2021; 41: 298-308
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Scan” (ONH-RC) and one “Posterior Pole N Scan” (PPoleN) for each eye, after maximal dilation. The OCT assessments were performed using triplicate scans of high quality
(Q values .20). Borders of the retinal layers were manually
adjusted when algorithm errors were detected.
HVF and OCT analyses were also masked to BCVA,
CS, ophthalmic examinations, and duration of visual loss.

Statistical Approach
Statistical analyses were performed using SAS.
Software version 9.4 (SAS Institute, Cary, NC).
Summary statistics for continuous variables were described
using N, mean standardization, and range. This approach was
applied both to independent data (e.g., age) and to dependent
data representing both eyes from the same subject. Numbers
and percentages were described in the same manner, representing both independent and dependent summaries. Analyses
of dependent data were performed using a mixed-effects
analysis of variance and the covariance between paired eyes
was determined by the model.
The monthly rates of loss of visual function and retinal
anatomy were estimated based on a linear ﬁt from mixedeffect models of individual data points collected at baseline
and plotted relative to onset of vision loss. They represent
the slope of the linear ﬁt derived from the scatterplot of
individual data for a given visual parameter over time since
onset. The eyes with no vision loss were included in the
regression model, with a duration of vision loss set to zero.
A locally estimated scatterplot smoothing (LOESS)
nonparametric, local regression model was used on the
individual data points. The resulting curve depicting the
evolution of visual and anatomical parameters over time was
based on a series of polynomial regressions around each data
point. The regressions used a limited look back and look
forward, giving distant points less weight.

RESULTS
Demographic Characteristics
Seventy-six subjects with LHON conﬁrmed to carry the
m.11778G.A mutation were included from both studies,
39 from RESCUE and 37 from REVERSE. Participants
were on average 35 years of age and mostly men (61
(80.2%) of 76 patients) (Table 1). Mean age and gender
distribution were similar in both trials. Overall, 26 (34.2%)
of 76 subjects reported simultaneous bilateral onset of
vision loss.

Duration of Vision Loss
As expected from the study design, the mean duration of
vision loss was shorter in RESCUE (3.7 months/112.1
days) than in REVERSE (8.9 months/271.0 days) (Table
1). This difference was statistically signiﬁcant (P , 0.0001).
Moster et al: J Neuro-Ophthalmol 2021; 41: 298-308

Visual Function: BCVA, CS, and HVF
Best-Corrected Visual Acuity
At baseline, BCVA was on average more preserved in
RESCUE subjects compared with REVERSE subjects, a
difference that was statistically signiﬁcant (1.29 LogMAR
[20/400 Snellen] and 1.61 LogMAR [20/800 Snellen]
respectively, P = 0.0029) (Table 1). In RESCUE, 4 eyes
had normal visual acuity ($20/20) at baseline, as monocular vision loss was allowed for inclusion in this study (see
Supplemental Digital Content 1, Supplementary Table
1, http://links.lww.com/WNO/A484).
BCVA values, collected and analyzed per eye in both
studies at screening and inclusion (for a total of 304
observations in 152 eyes), were grouped, averaged and
plotted as a function of duration of vision loss (Fig. 1A).
Cross-sectional BCVA values substantially worsened in the
ﬁrst 8 months (w250 days) after onset of vision loss, and
were globally off-chart after 8 months of vision loss. These
results were validated by a nonparametric LOESS regression
model (see Supplemental Digital Content 2, Supplementary Figure 3, http://links.lww.com/WNO/A475).
Linear regression on individual data points showed that
each additional month after symptom onset was associated
with a +0.24 logMAR difference in BCVA during the 0–6month period, compared with a +0.02 logMAR difference
during the 6–12 month period (Table 2).

Contrast Sensitivity
At baseline, CS was on average more preserved in RESCUE
subjects compared with REVERSE subjects, a difference that
was statistically signiﬁcant (0.62 LogCS and 0.30 LogCS
respectively, P = 0.0031) (Table 1). In REVERSE, 27/74
(36.5%) eyes were off-chart for CS at inclusion (i.e., these
eyes could not correctly read 2 letters at the maximum contrast possible on the Pelli–Robson chart). In RESCUE, all
eyes were on-chart for CS at inclusion. As per protocol, the
value assigned to off-chart eyes was the worst possible score (0
LogCS), enabling the inclusion of all eyes in CS analyses.
Baseline CS values collected in both studies were averaged
and plotted as a function of duration of vision loss (Fig. 1B).
Cross-sectional CS values declined similarly as BCVA measures in the ﬁrst 8 months (w250 days) of vision loss, then
were globally around 0.3 LogCS (equivalent to a detection
threshold of 50% contrast when normal control subjects can
detect on average a 1.6% contrast [1.8 LogCS]) (20). These
results were validated by a nonparametric LOESS regression
model (see Supplemental Digital Content 3, Supplementary Figure 4, http://links.lww.com/WNO/A476).
Linear regression on individual data points showed that
each additional month after symptom onset was associated
with a 20.15 LogCS difference in CS during the 0–6
month period, compared to a +0.01 LogCS difference during the 6–12 month period (Table 2).
301
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TABLE 1. Demographic characteristics—Visual function and retinal anatomy before treatment

N subjects
N males (%)
Age (years)
Mean (SD)
Min; max
Simultaneous bilateral onset
N subjects (%)
Duration of vision loss (days)†
N eyes
Mean (SD)
Min; max
N eyes
BCVA (LogMAR)
Mean (SD)
Min; max
Contrast sensitivity (LogCS)
Mean (SD)
Min; max
HVF mean deviation (dB)‡
Mean (SD)
Min; max
HVF pattern SD (dB)‡
Mean (SD)
Min; max
GCL macular volume (mm3)
Mean (SD)
Min; max
ETDRS total macular volume (mm3)
Mean (SD)
Min; max
RNFL temporal quadrant (mm)
Mean (SD)
Min; max
PMB RNFL thickness (mm)
Mean (SD)
Min; max
Average RNFL thickness (mm)
Mean (SD)
Min; max

All

RESCUE

REVERSE

76
61 (80.2%)

39
32 (82.0%)

37
29 (78.4%)

35.3 (15.3)
15; 69

36.3 (15.5)
15; 69

34.2 (15.2)
15; 67

0.5451

26 (34.2%)

19 (48.7%)

7 (18.9%)

0.0062

147
192.1 (95.0)
24; 364
152

73
112.1 (42.8)
24; 179
78

74
271.0 (59.5)
181; 364
74

1.45 (0.54)
20.20; 3.17

1.29 (0.56)
20.20; 2.51

1.61 (0.46)
0.70; 3.17

0.0029

0.46 (0.51)
0; 1.65

0.62 (0.54)
0; 1.65

0.30 (0.43)
0; 1.50

0.0031

224.4 (10.9)
234.7; 21.9

219.9 (12.1)
234.7; 21.9

229.0 (7.2)
234.6; 25.1

0.0039

5.9 (3.4)
1.3; 13.0

6.5 (3.6)
1.3; 13.0

5.3 (3.1)
1.7; 12.6

0.1865

0.63 (0.16)
0.42; 1.28

0.73 (0.17)
0.50; 1.28

0.53 (0.066)
0.42; 0.72

,0.0001

8.12 (0.51)
6.54; 9.58

8.40 (0.47)
7.54; 9.58

7.83 (0.36)
6.54; 8.75

,0.0001

39.2 (19.2)
13.5; 147.5

49.6 (20.9)
24.5; 147.5

28.2 (8.0)
13.5; 62.5

,0.0001

29.2 (12.7)
1.5; 123.0

34.8 (14.4)
21.0; 123.0

23.4 (6.7)
1.5; 39.5

,0.0001

84.8 (23.3)
39.5; 162.0

99.1 (18.2)
47.0; 162.0

69.7 (18.1)
39.5; 116.5

,0.0001

P*

0.7770

,0.0001

Means were calculated based on data collected at inclusion for BCVA, CS, and HVF. For OCT parameters, the means were calculated
based on the average values of data collected at screening and inclusion.
*P-values compare results from RESCUE and REVERSE.
†
The onset of vision loss was based on patient testimony; the duration of vision loss was assessed at screening in eyes with vision loss
perceived by the patient. In RESCUE, 4 eyes had no vision loss and one eye had vision loss not perceived by the patient (LogMAR +0.1 [20/
25]); these 5 eyes were not included in the calculation of mean duration of vision loss.
‡
Means were calculated in 65 eyes with reliable HVF test results at study inclusion (33 in RESCUE and 32 in REVERSE).

Mean Deviation of HVF
At baseline, 65 (42.8%) of 152 eyes had reliable HVF 30-2
test results: 33 (42.3%) of 78 eyes in RESCUE and 32
(43.2%) of 74 eyes in REVERSE. The average mean
deviation of HVF 30-2 was signiﬁcantly worse in REVERSE
subjects compared with RESCUE subjects, with 229.0 dB
and 219.9 dB, respectively (P = 0.0039) (Table 1).
Mean deviation (MD) values from reliable HVF tests,
collected in both studies at screening and inclusion (for a
total of 128 reliable observations in 110 eyes), were
grouped, averaged, and plotted as a function of duration
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of vision loss (Fig. 1C). Similar to BCVA and CS, crosssectional HVF MD values substantially worsened in the ﬁrst
8 months (w250 days) after onset of vision loss. These
results were validated by a nonparametric LOESS regression
model (see Supplemental Digital Content 4, Supplementary Figure 5, http://links.lww.com/WNO/A477).
Linear regression on individual data points showed that
each additional month after symptom onset was associated
with a 22.55 dB difference in HVF MD during the 0–6
month period, compared to a +0.40 dB difference during
the 6–12 month period (Table 2).
Moster et al: J Neuro-Ophthalmol 2021; 41: 298-308
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Pattern Standard Deviation of HVF
At baseline, the average pattern standard deviation (PSD) of
HVF 30-2 was similar in RESCUE and REVERSE eyes,
with 6.5 and 5.3 dB, respectively (P = 0.1865) (Table 1).
PSD values from reliable HVF tests, collected in both
studies at screening and inclusion (for a total of 128
reliable observations in 110 eyes), were grouped, averaged,
and plotted as a function of duration of vision loss (see
Supplemental Digital Content 5, Supplementary Figure 1B, http://links.lww.com/WNO/A473). Crosssectional PSD values increased during the ﬁrst 100 days
after onset of vision loss, and then decreased. These results
were validated by a nonparametric LOESS regression
model (see Supplemental Digital Content 6, Supplementary Figure 6, http://links.lww.com/WNO/A478).
Linear regression on individual data points showed
that each additional month after symptom onset was
associated with a +0.44 dB difference in HVF PSD during the 0–6-month period, compared with a 20.30 dB
difference during the 6–12 month period (Table 2).

Retinal Anatomy: SD-OCT Assessment

FIG. 1. Visual function parameters up to one year after
onset of vision loss in subjects with LHON harboring the
m.11778G.A mutation. N: number of observations pooled
together to calculate the means. Individual values were
collected at screening and inclusion, then grouped and
averaged by time since onset of vision loss. Because of a
very low number of observations available before onset of
vision loss, no standard error was calculated. A. Best-corrected visual acuity, B. contrast sensitivity, C. HVF mean
deviation. HVF, Humphrey Visual Field; LHON, Leber
hereditary optic neuropathy.
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The analyses of retinal anatomy focused on the thickness
and volume of the retinal layers most affected in LHON
subjects, the GCL and RNFL. Both these retinal parameters
showed more advanced loss in REVERSE subjects compared with RESCUE subjects (P , 0.0001) (Table 1). The
average GCL macular volume was 0.530 mm3 vs
0.734 mm3 in RESCUE and REVERSE, respectively, and
the average RNFL thickness in the temporal quadrant was
28.2 mm vs 49.6 mm, respectively.
Baseline OCT parameters collected in both studies
were averaged and plotted as a function of duration of
vision loss (Fig. 2 and see Supplemental Digital Content 5, Supplementary Figure 1A, 1C, http://links.lww.
com/WNO/A473). All cross-sectional OCT parameters
dramatically deteriorated in the ﬁrst 8 months (w250
days) after onset of vision loss and were then globally stable.
These results were validated by a nonparametric LOESS
regression models (see Supplemental Digital Contents
7–11, Supplementary Figures 7–11, http://links.lww.com/
WNO/A479, http://links.lww.com/WNO/A480, http://
links.lww.com/WNO/A481, http://links.lww.com/WNO/
A482, http://links.lww.com/WNO/A483).
Based on cross-sectional data, linear regression on
individual data points showed that, in the ﬁrst 6 months
after onset of vision loss, the monthly structural loss was on
average: 20.06 mm3 of GCL macular volume, 20.07 mm3
of ETDRS total macular volume, 26.00 mm of RNFL
thickness in the temporal quadrant, 25.76 mm of RNFL
thickness in the papillomacular bundle, and 23.06 mm of
average RNFL thickness (Table 2).

303

Clinical Research: Epidemiology Meets Neuro-Ophthalmology
TABLE 2. Monthly rates of change in visual parameters
Monthly Rate Estimate

BCVA (LogMAR)
Estimate
95% CI
P-value
CS (LogCS)
Estimate
95% CI
P-value
HVF MD (dB)
Estimate
95% CI
P-value
HVF PSD (dB)
Estimate
95% CI
P-value
GCL macular volume (mm3)
Estimate
95% CI
P-value
ETDRS total macular volume (mm3)
Estimate
95% CI
P-value
RNFL temporal quadrant (mm)
Estimate
95% CI
P-value
PMB RNFL (mm)
Estimate
95% CI
P-value
Average RNFL (mm)
Estimate
95% CI
P-value

All

RESCUE

REVERSE

+0.08
0.061 to 0.104
,0.0001

+0.24
0.201 to 0.278
,0.0001

+0.02
20.013 to 0.052
0.2503

20.05
20.073 to 20.032
,0.0001

20.15
20.197 to 0.111
,0.0001

+0.01
20.014 to 0.034
0.4235

20.62
21.095 to 20.136
0.0141

22.55
23.863 to 21.230
0.0007

+0.40
20.066 to 0.871
0.1000

20.08
20.283 to 0.116
0.4159

+0.44
20.170 to 1.059
0.1669

20.30
20.502 to 20.098
0.0059

20.03
20.033 to 20.024
,0.0001

20.06
20.068 to 20.053
,0.0001

20.01
20.013 to 20.003
0.0023

20.04
20.052 to 20.026
,0.0001

20.07
20.087 to 20.049
,0.0001

20.01
20.028 to 0.011
0.3869

22.71
23.269 to 22.160
,0.0001

26.00
27.174 to 24.830
,0.0001

20.43
20.848 to 20.005
0.0502

22.06
22.552 to 21.561
,0.0001

25.76
26.846 to 24.673
,0.0001

20.02
20.616 to 0.569
0.9392

23.25
23.890 to 22.611
,0.0001

23.06
24.493 to 21.635
,0.0001

22.49
23.135 to 21.844
,0.0001

BCVA, best-corrected visual acuity; CS, contrast sensitivity; CI, conﬁdence interval; ETDRS, Early-Treatment Diabetic Retinopathy Study;
GCL, ganglion cell layer; HVF, Humphrey visual ﬁeld; MD, mean deviation; PMB, papillomacular bundle; PSD, pattern SD; RNFL, retinal nerve
ﬁber layer.

Eyes Unaffected by BCVA Loss
Four eyes were not affected by BCVA loss at the time of study
enrollment in RESCUE (see Supplemental Digital Content 1,
Supplementary Table 1, http://links.lww.com/WNO/A484).
Although they all had normal BCVA (#0.0 LogMAR), they
were already showing signs of loss of CS, with values below 1.8
LogCS. When HVF tests were reliable, MD values ranged from
22.4 to 21.14 dB and PSD values ranged from 1.29 to
1.87 dB. In the 4 eyes assessed before onset of vision loss, an
increase of thickness/volume was observed in all retinal layers of
interest: GCL, RNFL in the temporal quadrant and papillomacular bundle, RNFL average thickness, and ETDRS total macular volume. A detailed description of these 4 eyes, including
fundus photographs, HVFs, peripapillary RNFL thickness per
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quadrant, and GCL macular thickness and volume, is provided
in Supplemental Digital Content 12, (see Supplementary
Figure 2, http://links.lww.com/WNO/A474).

CONCLUSION
We present a large data set of retinal anatomic measurements and visual function ascertained during the ﬁrst year
following visual loss in LHON subjects carrying the
m.11778G.A mutation. Our cross-sectional data collection was performed at screening (#1 month pretreatment) and inclusion (1 day pretreatment), shortly
before patients received gene therapy in one eye. As such,
this report does not constitute a longitudinal study of the
Moster et al: J Neuro-Ophthalmol 2021; 41: 298-308
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FIG. 2. Retinal parameters up to one year after onset of
vision loss in subjects with LHON harboring the
m.11778G.A mutation. N: number of observations pooled
together to calculate the means. Individual values were
collected at screening and inclusion, then grouped and
averaged by time since onset of vision loss. Because of a
very low number of observations available before onset of
vision loss, no standard error was calculated. A. Ganglion
cell layer macular volume, B. Retinal nerve ﬁber layer (RNFL)
temporal quadrant thickness, C. Average RNFL thickness.
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natural history of untreated individuals with LHON. Nonetheless, since enrollment in the RESCUE and REVERSE
clinical trials spanned the course of one year from onset of
vision loss, the collected data allowed for cross-sectional
analysis of the natural history of LHON over the ﬁrst year
after onset.
Our ﬁndings are in keeping with the evolution of the
disease process in LHON. Unsurprisingly, longer durations
of vision loss were associated with worse retinal anatomy
parameters and visual function. All cross-sectional functional (BCVA, CS, and HVF) and retinal anatomic
measurements (GCL macular volume, RNFL thickness,
and total macular volume) drastically worsened in approximately the ﬁrst 8 months after onset, and were then
globally stable. The deterioration of OCT anatomic
parameters lagged slightly behind the visual functions.
However, pathological thickening of these retinal structures
before visual loss and in the early stages of visual decline, as
particularly demonstrated in those patients with presymptomatic second eyes at baseline, may have contributed partly
to this delay in measurable deterioration.
The loss of function and retinal structure was more
pronounced at later cross-sectional data points and ultimately
correlated with the degree of visual acuity deﬁcit. In 2017, a
consortium of LHON experts established 3 stages in the
disease progression: the “subacute” phase, the “dynamic”
phase, and the “chronic” phase (2). The international consensus statement on the clinical and therapeutic management
of LHON deﬁned the ﬁrst 6 months after onset as the subacute or acute phase, depending on how rapidly the loss of
central vision evolves. Visual acuity usually stabilizes between
4 and 6 months after onset, but other clinical metrics such as
visual ﬁelds and OCT measurements may still evolve in the
dynamic phase, up to 12 months after onset. One year after
onset, visual function and retinal anatomy should have plateaued and the patient typically transitions into the chronic
stage of the disease (2). Our results align with the description
of the subacute and dynamic phases observed over the ﬁrst
year of the disease. In this cross-sectional analysis, BCVA
stabilized a bit later at approximately 8 months after onset.
The demographic characteristics of LHON subjects were
similar between the RESCUE and REVERSE trials. The
cohorts recruited for both studies were aligned with a typical
LHON population as regards gender and age distributions
(80% men, mean age at onset 35 years old) (2–4,6,9).
Based on protocol inclusion criteria, only the average duration of vision loss at enrollment was signiﬁcantly different
between studies. As expected, this difference in duration of
vision loss was associated with worse visual functions and
anatomic structural parameters in the REVERSE population, compared to RESCUE.
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One year after onset of vision loss, the ﬁnal average
BCVA was off chart. CS followed a similar pattern of acute
decline. Our cross-sectional data showed that the visual ﬁeld
deteriorated as well, ﬁrst with the appearance of focal
defects, mainly a central scotoma, which is the hallmark of
LHON, resulting in an increase in PSD. Then, the overall
diffuse deterioration of the visual ﬁeld caused a slow
decrease in PSD, as observed in eyes with more than 6
months of vision loss. Of note, only reliable HVF tests were
included in this analysis, resulting in more than half of the
data being excluded.
Overall, the dramatic BCVA drop reported in this crosssectional analysis is consistent with the poor visual prognosis
associated with the m.11778G.A mtDNA mutation reported in a recent natural history meta-analysis (9). Among
204 LHON subjects carrying the primary MT-ND4 mutation and aged 15 or older at onset, spontaneous recovery
was detected in only 11% of cases (9).
Based on cross-sectional data, our results support previous
work reporting relatively rapid loss of retinal tissues in the
ﬁrst few months following onset of vision loss in LHON
patients (21–25). The dramatic loss of tissue occurs during
the subacute and dynamic phases of the disease and reaches a
nadir a short time after the nadir of visual acuity. During the
subacute phase, there is evidence that the thinning in the
GCL occurs before the thinning in the RNFL, the average
RNFL thickness being relatively stable (24). Further deterioration may remain undetected by a “ﬂoor effect” because of
technical limitations of currently available OCT platforms.
On the other end of the spectrum, the 4 eyes with normal
visual acuity at enrollment shed light on the changes in
retinal anatomy that precede the onset of BCVA loss. As
previously described in other studies, assessment of key anatomic parameters showed presymptomatic increase of thickness of the RNFL, macular volume, and GCL volume,
suggestive of evolving swelling heralding the imminent occurrence of visual symptoms (22,24,25). Interestingly, worsening of CS may also be a harbinger of the onset of BCVA loss,
because eyes with preserved BCVA were already showing CS
impairment. The occurrence of BCVA loss perhaps can be
viewed as the ultimate outcome of anatomic and visual function (CS) changes that began at an earlier phase of the disease
expression process (22,25). However, it should be noted that
many patients in the acute phase of LHON may not have
visible or demonstrable RNFL thickening (6), and, conversely, the presence of transient RNFL thickening in asymptomatic carriers who never proceed to symptomatic visual loss
makes it difﬁcult to use anatomic or functional measures as
predictors of visual outcome (26,27).
The limitations of our analyses are related to the crosssectional nature of the data, as subjects naive to LHON
treatment were subsequently administered gene therapy and
not followed longitudinally as untreated individuals. Thus,
our reconstruction of the events occurring as the natural
history during the ﬁrst year after onset of visual loss is not
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based on the preferred prospective follow-up of individual
patients, but rather on the collection of independent crosssectional data points. However, the data assembled from
these 2 trials provide a valuable landscape of the clinical
characteristics of LHON patients harboring the
m.11778G.A mutation in MT-ND4, and the crosssectional evolution of key visual functional and anatomic
parameters over one year. Our study thus broadens the characterization of LHON, and affords complementary evidence
supporting the use of BCVA as the key endpoint currently
available to assess the efﬁcacy of LHON therapy (15,16).
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